Table 1: Inhibitory concentration 50 (IC50) of the major pharmaceutical compounds in clinical development for the treatment of thyroid cancer segregated with respect to the kinase activity required to inhibit different molecular targets (nmol/L).

Pharmaceutical compoundVEGFR1VEGFR2VEGFR3RETRET/PTCPDGFRβBRAFKITOthers (IC50)

Sorafenib2690204750572568
Motesanib23659848
Axitinib0.10.20.291.221.7
Sunitinib101010100224391–10
Vandetanib40110130100EGFR (500)
Pazopanib1030478474
Lenvatinib (E7080)2245.23539FGFR1 (46)
Cabozantinib (XL-184)0.0354C-MET (1.8)